CrushSCI.com
159.5Average days
156Median days
44Fastest days
303Longest days
1682025 publications

Paper Review Records

All Paper Review Records

21 valid samples · Newest publication first
Review days = acceptance date − received date. PDF, DOI, and publisher-page sources are retained.

119 days

Mapping Two Decades of KRAS-Targeted Drug Development in Cancer: A Bibliometric Analysis of Scientific Evolution and Emerging Therapeutic Trends

Authors
Aly Samy Aly; Zaid Yacoub; Jad YacoubShow moreShow less
Affiliations
1. School of Medicine, Royal College of Surgeons in Ireland, Dublin, IrelandShow moreShow less
Source PDF DOI Publisher page
133 days

Leveraging Regulatory Reliance to Streamline Management of CMC Post-Approval Changes: Industry insights from Multi-Country Reliance Pilots

Authors
Mónica Perea-Vélez; Marie Kirman; Anjana Patel; Mark Pellett; Mandy Tyler-Mahon; Thomas F. Perrone; Cynthia Ban; Susanne Ausborn; Frank MontgomeryShow moreShow less
Affiliations
1. GlaxoSmithKline, Wavre, Belgium; 2. AstraZeneca, Macclesfield, Cheshire, UK; 3. Pfizer Ltd, Surrey, UK; 4. AstraZeneca, Cambridge, UK; 5. GlaxoSmithKline, London, UK; 6. GlaxoSmithKline, Waltham, USA; 7. Sanofi, North York, Canada; 8. Roche, Basel, SwitzerlandShow moreShow less
Source PDF DOI Publisher page
129 days

Japanese Patient Enrollment in Multi-regional Clinical Trials for New Drug Applications in Japan: Current Status and Related Factors

Authors
Ito Furukawa; Mamoru NarukawaShow moreShow less
Affiliations
1. Department of Clinical Medicine (Pharmaceutical Medicine), Graduate School of Pharmaceutical Sciences, Kitasato University, Minato‑ku, Japan; 2. Sanofi Specialty Care Medical, Tokyo, JapanShow moreShow less
Source PDF DOI Publisher page
166 days

Investigator-Initiated Trials as a Clinical Development Approach for Orphan Drugs Compared with Industry-Sponsored Trials in Japan

Authors
Shingo Yamaguchi; Eiji Nakatani; Ryuta AsadaShow moreShow less
Affiliations
1. Department of Medical Research and Development Strategy, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan; 2. Laboratory of Biostatistics, NHO Nagoya Medical Center, Nagoya, JapanShow moreShow less
Source PDF DOI Publisher page
213 days

The Role of Digital Twins in Clinical Trials: A New Perspective on Methodological and Statistical Challenges

Authors
Fatma Nur CicinShow moreShow less
Affiliations
1. Department of Management Information Systems, Faculty of Economics, Administrative and Social Sciences, Istinye University, Istanbul, TürkiyeShow moreShow less
Source PDF DOI Publisher page
74 days

Accelerated Registration of a New Anti-infective Combination in ASEAN Markets: Experience, Insights and Learnings on the ASEAN Joint Assessment (ASEAN JA)

Authors
Paul Marvin Quizon; Patriz Miga Lintag-Raymundo; Wan Lee Chow; Serene Huang; Thanh Tu Nguyen; R. Iin Nurhayati; Wipada Rodtanaporn; Tse Siang KangShow moreShow less
Affiliations
1. Pfizer, Inc, Makati City, Philippines; 2. Pfizer (Malaysia) Sdn. Bhd, Kuala Lumpur, Malaysia; 3. Pfizer Pte. Ltd, Singapore, Singapore; 4. Pfizer (Vietnam) Ltd. Co, Hanoi, Vietnam; 5. PT Pfizer Indonesia, Jakarta, Indonesia; 6. Pfizer (Thailand) Ltd, Bangkok, ThailandShow moreShow less
Source PDF DOI Publisher page

FAQ

How long does Therapeutic Innovation & Regulatory Science take to review a manuscript?

As of 2026-11-19, CrushSCI has 21 complete review records for Therapeutic Innovation & Regulatory Science. The fastest paper went from submission to acceptance in 44 days (Identifying and Deploying Benchmarks for Clinical Research at Sites, received 2026-02-04, accepted 2026-03-20); the slowest took 303 days. The average is 159.5 days and the median is 156 days.

Expert Matching · Case Demo

Turn Your Submission Goalsinto a Verifiable Journal Plan

Share your field, deadline, and author profile. CrushSCI uses real review records to suggest a title direction, shortlist journals, and estimate timelines.

We will reply within 30 minutes.

CrushSCI online

Client

I work in environmental engineering and need an SCI paper published within three months. I have no grant funding or prominent co-author. Which journals could I target?

CrushSCI

Yes. We will first screen for feasibility against the 90-day deadline, then identify comparable papers without grant support or prominent co-authors. The final shortlist will prioritize research quality and journal scope.

Suggested title
Machine Learning and Life-Cycle Assessment for Predicting and Optimizing Carbon Emissions in Urban Wastewater Treatment

SampleLatest 5 valid paper samples from 2026

Average review59.6 days

Median65 days

Contact CrushSCI

Contact CrushSCI

Leave your email address to discuss academic polishing, structural refinement, or one-to-one guidance.

We will reply within 30 minutes.

Selected service: Academic Consulting Service

Leave your email address

Or email us directly at leader@crushsci.com

Enter your email address so we can reply. Your details will remain private.